Together, three tumor antigens (CD247, FCGR1A, and TRRAP) were identified as potential candidates for the CHOL-mRNA vaccine with potential immune provocative effects and can be processed and presented by antigen-presenting cells (APCs) to induce a tumor response. This evidence concerns the gene TRRAP and neoplasm.